Hirschsprung's disease (HSCR) and anorectal malformations (ARM) comprise a spectrum of congenital disorders that affect the distal gastrointestinal tract. HSCR is typified by aganglionosis, the ...

Neurenati Announces its First Scientific and Clinical Advisory Board Meeting with KOLs to Advance the Development of NEU-001, a Promising Cure for Hirschsprung Disease Neurenati, an innovative ...

Neurenati Therapeutics Inc.’s NEU-001 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Hirschsprung disease.